Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

4. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing
hormone agonist in treatment of premenstrual symptoms with
and without ongoing dysphoria: a controlled study. Psychopharmacol
Bull 1997; 33:303–9.
5. Mortola AJF, Girton L, Fischer U. A successful treatment of
severe premenstrual syndrome by combined use of gonadotropinreleasing
hormone agonist and estrogen/progestin. J Clin
Endocrinol Metab 1991; 72:252A–F.
6. Brown CS, Ling FW, Andersen RN et al. Efficacy of depot leuprolide
in premenstrual syndrome: effect of symptom severity and
type in a controlled trial. Obstet Gynecol 1994; 84:779–86.
7. Casper RF, Heart MT. The effect of hysterectomy and bilateral
oophorectomy in women with severe premenstrual syndrome.
Am J Obstet Gynecol 1990; 162:105–9.
8. Casson P, Hahn PM, Van Vugt DA et al. Lasting response to
ovariectomy in severe intractable premenstrual syndrome. Am J
Obstet Gynecol 1990; 162:99–105.
9. Wyatt K, Dimmock P, Jones P et al. Efficacy of progesterone and
progestogens in management of premenstrual syndrome: systematic
review. BMJ 2001; 323:776–80.
10. Rapkin AJ. A review of treatment of premenstrual syndrome and
premenstrual dysphoric disorder. Psychoneuroendocrinology
2003; 28(Suppl 3):39–53.
11. Eriksson E, Sundblad C, Landen M et al. Behavioral effects of
androgens in women. In: Steiner M, Yonkers KA, Ericksson E,
eds. Mood Disorders in Women. London: Martin Dunitz;
2000:233–46.
12. Steiner M, Dunn EJ, MacDougall M et al. Serotonin transporter
gene polymorphism, free testosterone, and symptoms associated
with premenstrual dysphoric disorder. Biol Psychiatry 2002;
51:91S.
13. Freeman EW, Rickels K, Sondheimer SJ et al. A double-blind trial
of oral progesterone, alprazolam, and placebo in treatment of
severe premenstrual syndrome. JAMA 1995; 274:51–7.
14. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology
on functioning and treatment-seeking behavior: experience
from the United States, United Kingdom, and France.
J Womens Health Gend Based Med 1999; 8:1043–52.
15. Fuhrmann U, Krattenmacher R, Slater EP et al. The novel progestin
drospirenone and its natural counterpart progesterone:
biochemical profile and antiandrogenic potential. Contraception
1996; 54:243–51.
16. Walker A, Bancroft J. Relationship between premenstrual symptoms
and oral contraceptive use: a controlled study. Psychosom
Med 1990; 52:86–96.
17. Backstrom T, Hansson-Malmstrom Y, Lindhe BA et al. Oral contraceptives
in premenstrual syndrome: a randomized comparison
of triphasic and monophasic preparations. Contraception 1992;
36:257–66.
18. Backstrom T, Andreen I, Birzniece V et al. The role of hormones
and hormonal treatments in premenstrual syndrome. CNS Drugs
2003; 17:325–42.
19. Graham CA, Sherwin BB A prospective treatment study of premenstrual
symptoms using a triphasic oral contraceptive.
Psychosom Res 1992; 36:257–66.
20. Freeman EW, Kroll R, Rapkin A et al. Evaluation of a unique oral
contraceptive in the treatment of premenstrual dysphoric disorder.
J Womens Health Gend Based Med 2001; 10:561–9.
21. Yonkers KA, Brown C, Pearlstein RB et al. Efficacy of a new
low-dose oral contraceptive with drospirenone in premenstrual
dysphoric disorder. Obstet Gynecol 2005; 106:492–501.
22. Vellacott ID, O’Brien PM. Effect of spironolactone on premenstrual
syndrome symptoms. J Reprod Med 1987; 32:429–54.
23. Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a
placebo-controlled efficacy study with spironolactone and medroxyprogesterone
acetate. Int J Gynaecol Obstet 1991; 34:243–7.
HORMONAL THERAPIES OVERVIEW 115
24. Aslaksen K, Falk V. Spironolactone in the treatment of premenstrual
tension: a double-blind study of spironolactone versus
bendroflumethiazide and placebo. Cur Ther Res Clin Exp 1991;
49:120–5.
25. Schmidt JB, Spona J. The levels of androgen in serum in female
acne patients. Endocrinol Exp 1985; 19:17–21.
26. Dougherty DM, Bjork JM, Moeller PG et al. The influence of
menstrual cycle phase on the relationship between testosterone
and aggression. Physiol Behav 1997; 62:431–6.
27. Eriksson E, Sundblad C, Lisjo P et al. Serum levels of androgens
are higher in women with premenstrual irritability and dysphoria
than in controls. Psychoneuroendocrinology 1992; 17:195–204.
28. Slap GB. Oral contraceptives and depression: impact, prevalence
and cause. J Adolesc Health Care 1981; 2:53–64.
29. Kahn LS, Halbreich U. Oral contraceptives and mood. Expert
Opin Pharmacother 2001; 2:1367–82.
30. Sulak PJ, Scow RD, Preece D et al. Hormone withdrawal symptoms
in oral contraceptive users, continuous use. Obstet Gynecol
2000; 95:261–6.
31. Magos AL, Brincat M, Studd JW. Treatment of the premenstrual
syndrome by subcutaneous estradiol implants and cyclical oral
norethisterone: placebo-controlled study. Br Med J (Clin Res Ed)
1986; 292:1629–34.
32. Magos AL, Collins WP, Studd JW. Management of the premenstrual
syndrome by subcutaneous implants of oestradiol.
J Psychosom Obstet Gynecol 1984; 3:93–9.
33. Watson NR, Studd JWW, Savvas M et al. Treatment of severe premenstrual
syndrome with oestradiol patches and cyclical oral
norethisterone. Lancet 1989; 2:730–2.
34. Smith RN, Studd JW, Zamblera D et al. A randomized comparison
over 8 months of 100 micrograms and 200 micrograms twice
weekly doses of transdermal oestradiol in the treatment of severe
premenstrual syndrome. Br J Obstet Gynaecol 1995; 102:475–84.
35. Watson NR, Studd JW, Savvas M et al. The long-term effects of
estradiol implant therapy for the treatment of premenstrual
syndrome. Gynecol Endocrinol 1990; 4:99–107.
36. Dalton K. The Premenstrual Syndrome and Progesterone
Therapy, 2nd edn. Chicago, IL: Year Book Medical Publishers;
1984.
37. Freeman E, Rickels K, Sondheimer SJ et al. Ineffectiveness of
progesterone suppository treatment for premenstrual syndrome.
JAMA 1990; 264:349–53.
38. Dennerstein L, Spencer-Gardner C, Gotts G et al. Progesterone
and the premenstrual syndrome: a double-blind crossover trial.
BMJ 1985; 290:1617–21.
39. West CP. Inhibition of ovulation with oral progestins – effectiveness
in premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol
1990; 34:119–28.
40. Dennerstein L, Morse C, Gotts G et al. Treatment of premenstrual
syndrome: a double-blind trial of dydrogesterone. J Affect Disord
1986; 11:199–205.
41. Williams JGC, Martin AJ, Hulkenberg-Tromp A. Premenstrual
syndrome in four European countries. Part 2. A double-blind controlled
study of dydrogesterone. Br J Sex Med 1983; 10:8–18.
42. Hahn PM, Van Vugt, DA, Reid RL. A randomized, placebocontrolled,
crossover trial of danazol for the treatment of premenstrual
syndrome. Psychoneuroendocrinology 1995; 20:193–209.
43. Gilmore DH, Hawthorn RJ, Hart DM. Danazol for premenstrual
syndrome: a preliminary report of a placebo-controlled doubleblind
study. J Int Med Res 1985; 13:129–30.
44. Watts JF, Edwards RL, Butt WR. Treatment of premenstrual syndrome
using danazol: preliminary report of a placebo-controlled,
double-blind dose ranging study. J Int Med Res 1985; 13:127–8.
45. Deeny M, Hawthorn R, McKay Hart D. Low dose danazol in the
treatment of the premenstrual syndrome. Postgrad Med J 1991;
67:450–4.